Romiplostim
Romiplostim is a pharmaceutical drug with 52 clinical trials. Currently 3 active trials ongoing. Historical success rate of 86.1%.
Success Metrics
Based on 31 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
26
Mid Stage
17
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
79.5%
31 of 39 finished
20.5%
8 ended early
3
trials recruiting
52
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Clinical Trials (52)
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA
TPO-Mimetic Use in Children for Hematopoietic Failure
Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study
Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Romiplostim in Chemotherapy-Induced Thrombocytopenia
Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy
Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 52